Association between androgen receptor expression, Ki-67 and the 21-gene recurrence score in non-metastatic, lymph node-negative, estrogen receptor-positive and HER2-negative breast cancer. Issue 10 (15th June 2015)

• Record Type: Journal Article
• Authors: Vera-Badillo, Francisco E; Chang, Martin C; Kuruzar, Gordana; Ocana, Alberto; Templeton, Arnoud J; Seruga, Bostjan; Goldstein, Robyn; Bedard, Philippe L; Tannock, Ian F; Amir, Eitan
• Is Part Of: Journal of clinical pathology. Volume 68:Issue 10(2015)
• Page Start: 839
• Page End: 843
• Publication Date: 2015-06-15
• Subjects: BREAST CANCER -- HORMONE -- MOLECULAR ONCOLOGY; Pathology -- Periodicals; Pathology, Molecular -- Periodicals; 616.0705
• DOI: 10.1136/jclinpath-2015-203012
• Languages: English
• ISSNs: 0021-9746

Abstract

Abstract : Background: The mechanisms underlying the favourable prognosis of androgen receptor (AR) expression in breast cancer are unknown. Methods: The associations between the 21-gene recurrence score (RS), AR, grade, mitotic score, Ki-67 and estrogen receptor (ER) and progesterone receptor (PgR) expression were explored in sequential women with lymph node-negative, ER-positive and HER2-negative breast cancer. Statistical significance of this exploratory study was defined as p<0.10. Results: Analysis comprised 70 women. Most tumours had high AR expression (97% had scores >3). Median RS was 15 (range 1–53). AR expression showed a minimally significant positive correlation with ER (R=0.37), but no correlation with Ki-67 (R=−0.18). In univariable analysis, AR (p=0.01), ER (p<0.001) and PgR (p<0.001) had significant negative associations with RS. Ki-67 (p=0.16), grade (p=0.40) and mitotic score (p=0.23) showed no association with RS. Multivariable analysis showed similar associations. Conclusions: AR is associated with lower RS, but not with Ki-67.